-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sickle cell disease (SCD) is an autosomal recessive, hematologic disorder that β globin mutations that cause hemoglobin S (HbS) to polymerize
The Phase 3 HESTIA3 study aimed to evaluate the efficacy and safety
Patients with SCD aged 2-17 years are randomly (1:1) divided into two groups and receive either tigrelor or a matched placebo based on body weight
Overall, a total of 193 patients from 16 countries were randomly assigned to the tegrelo group (101) or placebo group (92
The median platelet suppression rate at 6 months of tegrelor intervention was 34.
In summary, the prevention of the use of ticagrelol did not reduce the occurrence
Original Source:
Matthew M.